Why Did TransCode Therapeutics (RNAZ) Plunge 13.04%?

On April 3, 2025, TransCode Therapeutics, Inc. (RNAZ) experienced a significant drop of 13.04% in pre-market trading, reflecting a notable decline in investor sentiment.

Analysts have provided mixed forecasts for TransCode Therapeutics. One analyst has given the stock a "Strong Buy" rating with a 12-month price target of $20.00, suggesting a potential upside of 3,908.82%. However, other forecasts indicate a more cautious outlook, with predictions of a slight decline to $0.498468 per share by May 1, 2025.

TransCode Therapeutics has reported a net income of -$18.55 million and has generated $0.00 earnings per share over the last four quarters. This financial performance has likely contributed to the recent stock price volatility, as investors reassess the company's prospects.

Additionally, TransCode Therapeutics has been identified as one of the top stock losers over the past three years, further highlighting the challenges the company faces in regaining investor confidence.